Actualités et Activités de Foresight Diagnostics
Présence
Siège : Inde
Quest Diagnostics fait partie des...
Quest Diagnostics est une société cotée sous le symbole boursier DGX (US).
Quest Diagnostics a une présence directe dans 4 pays.Quest Diagnostics a 6 filiales dont Centogene, Foresight Diagnostics et Haystack Oncology.
Elles sont en:
- Biotechnologie57%
- Santé43%
Acquisition, funding and merger involving Quest Diagnostics.
- Natera has announced the acquisition of Foresight Diagnostics (publié le 5 décembre 2025).
Dirigeants
Voir l'organigramme avec ses 13 principaux dirigeants
Biographies les plus recherchées chez Foresight Diagnostics
- Jake Chabon, Chief Executive Officer and Chief Scientific Officer
- Wendy Yee, Vice President, Product Software
- Carrina Cappadona, Vice President, Patient and Client Experience
Changements de dirigeants chez Foresight Diagnostics
- Mckenzie Carlisle qui était Senior Director, Regulatory Operations & Compliance, devient Senior Director, Regulatory Affairs & Quality Assurance (publié le 10 mars 2026).
Changements de dirigeants chez Quest Diagnostics
- Mark Gardner, Senior Vice President, Oncology, Genomics and Research and Development, a quitté l'entreprise (publié le 17 juillet 2026).
- Timothy Wentworth, a rejoint l'entreprise comme Director (publié le 13 mars 2026).
- Benjamin Beauvalot, a rejoint l'entreprise comme Senior Vice President, Chief Strategy and Mergers and Acquisitions Officer (publié le 26 février 2026).
Créer une alerte
pour suivre les mouvements de dirigeants chez Foresight Diagnostics.
Biotechnologie
Quest Diagnostics a 2 428 concurrents dont Lonza (Suisse), Vertex Pharmaceuticals (Etats—Unis) et Eurofins (Luxembourg).
Actualités en fusion/acquisition en Biotechnologie.
- Eli Lilly has announced the acquisition of AtaiBeckley (publié le 17 juillet 2026).
- GSK a acquis Nuvalent (publié le 17 juillet 2026).
- Clearside Biomedical has gone out of its bankruptcy protection (publié le 15 juillet 2026).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Foresight Diagnostics
- Natera Acquires Foresight Diagnostics | foresight-dx.com
- Foresight Diagnostics Announces Multiple Presentations in Lymphoma Featuring PhasED-Seq™ Ultrasensitive MRD Analysis at the upcoming ASH Annual Meeting | foresight-dx.com
- Foresight Diagnostics to Present Clinical Performance Data on Foresight CLARITY™ MRD at IASLC 2025 World Conference on Lung Cancer | foresight-dx.com
- Foresight Diagnostics and Roche Enter Licensing Agreement for PhasED-Seq™ Technology in Non-Hodgkin's Lymphoma | foresight-dx.com
- Foresight Diagnostics Announces Publication of Landmark Study Demonstrating Prognostic Value of Ultrasensitive ctDNA-MRD Detection in Large B-Cell Lymphoma | foresight-dx.com
- Foresight Diagnostics and Partners to Present Independent Validation Data for its CLARITY™ MRD Assay at the 2025 European Hematology Association (EHA) Congress and International Conference on Malignant Lymphoma (ICML) | foresight-dx.com
- Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma | foresight-dx.com
- Foresight Diagnostics Presents Independent Validation of its CLARITY Minimal Residual Disease Assay in Multi-center Study of Frontline DLBCL at the 2025 ASCO Annual Meeting | foresight-dx.com
- Foresight Diagnostics to Participate in the Jefferies Global Healthcare Conference | foresight-dx.com
- Foresight Diagnostics and Partners to Present New Data on Ultra-sensitive Minimal Residual Disease Detection and Clinical Trial Progress at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | foresight-dx.com
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Foresight Diagnostics
- Foresight Diagnostics sur Wikipédia, Google News & Yahoo Finance en 1-click
- Foresight Diagnostics sur LinkedIn, X (Twitter) & YouTube en 1-click
